



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Applicant:

Yoram REITER et al

Serial No.: 10/073,301

Filed: February 13, 2002

For: Antibody Having a T-Cell Receptor-Like
Specificity, Yct Higher Affinity, and the
Use of Same in the Detection and
Treatment of Cancer, Viral Infection
and Autoimmune Disease

Examiner: Marianne NMN DiBrino

Group Art Unit: 1644

Attorney
Docket: 01/23094

ELECTION

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

This is in response to the United States Patent and Trademark Office
Restriction Action mailed October 4, 2004, which response is being made on or
before November 4, 2004.

Applicants hereby elect Group I, namely Claims 1 – 26 and 63, drawn to a
molecule comprising an antibody specifically bindable with an HLA class I/antigen
and composition thereof.

With respect to the specific molecule, Applicant selects a molecule
comprising an antibody with the sequence of SEQ ID NO: 9 specifically bindable
with HLA-A21/SEQ ID NO: 2 (gp100 peptide G9-209M, IMDQVPFSV).


2

With respect to species requirement of paragraph 13, Applicant selects fluorescent dye species of claim 6.

It is believed claims 1 - 26 and 63 are readable on the above species.

Applicants reserve the right to file, at a later date, additional divisional applications claiming priority from the present application which are directed to any one or more of the non-elected Groups.

Respectfully submitted,



Sol Sheinbein

Registration No. 25,457

Date: November 4, 2004